Exocrine Pancreatic Insufficiency Therapeutics Market Size, Global Trend and Industry Analysis By Applications and Leading Companies, Forecast By 2027

The global exocrine pancreatic insufficiency therapeutics market to reach USD 2.55 billion by 2026, exhibiting a CAGR of 6.5% during the forecast period. Increasing prevalence of diabetes worldwide is touted to be one of the core factors fueling the growth of this market. According to the International Diabetes Federation (IDF), in 2019, approximately 463 million adults were suffering from diabetes and by 2045, this figure will rise to 700 million. In the same year, the disease caused deaths of 4.2 million people and around 374 million people are at an increased risk of developing type 2 diabetes. Diabetes cause microvascular damage which reduce pancreatic volume, inducing pancreatic fibrosis. According to the National Institutes of Health, those afflicted by type 1 diabetes have a 30 to 50% chance of developing exocrine pancreatic insufficiency, while those with type 2 have a 20 to 30% chance of developing the disorder. Thus, the exocrine pancreatic insufficiency therapeutics market stands to gain as a result.

Request a Sample Copy of Research Report:https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/exocrine-pancreatic-insufficiency-market-100652

According the new Fortune Business Insights report, titled “Exocrine Pancreatic Insufficiency Therapeutics Market Size, Share & Industry Analysis, By Therapy (Pancreatic Enzyme Replacement Therapy (PERT), Nutritional Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Others) and Regional Forecast, 2019-2026”, the value of the market stood at USD 1.49 billion in 2018. The report also provides an elaborative overview of the general industry trends that will impact the development of the market in the forecast period. Additionally, the report also contains an in-depth analysis of the various factors and dynamics through a thorough research that will aid businesses to formulate strategies to gain traction in this promising market.

Exocrine Pancreatic Insufficiency (EPI) is a condition that occurs when the pancreas cannot secrete the required amount of digestive juices and enzymes to metabolize food and other nutrients. Symptoms of this condition include flatulence, diarrhea, bloating, and abdominal pain.

Steady Rise in the Incidence of Disorders Associated with EPI to Aid Growth

There are many conditions associated with exocrine pancreatic insufficiency such as celiac disease, cystic fibrosis, inflammatory bowel diseases, and pancreatic cancer. The prevalence of these associated disorders is on the rise, which is expected to ramp up the demand for exocrine pancreatic insufficiency treatment. This increasing demand has led to innovation in EPI medications and therapeutics that have enhanced the potential of this market. One of the most popular development in the market is the creation of the Pancreatic Enzyme Replacement Therapy (PERT) which is furthering the exocrine pancreatic insufficiency therapeutics market trends.

Have Any Query? Ask Our Experts:https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/exocrine-pancreatic-insufficiency-market-100652

Increasing Incidence of Gastrointestinal Disorders to Drive the Market in North America

Among regions, North America is slated to dominate the exocrine pancreatic insufficiency therapeutics market share in the forecast period, having generated USD 1.18 billion in 2018 in revenue. The main reasons for this is the increasing prevalence and awareness regarding gastrointestinal diseases in the region along with a high adoption rate of advanced treatment methods for EPI. Rising disposable incomes that have increased the uptake of EPI therapeutics would aid Asia-Pacific register the highest growth rate in this market. Awareness about associated disorders is growing speedily in countries such as Japan and India which will feed the market in the region. In Europe, the market is anticipated to be driven by the increasing penetration of exocrine pancreatic insufficiency medications.

Acquisitions and Regulatory Approvals to Spur Competition

Extensive global presence and strong product offerings are the two prime factors enabling key players in this market to maintain their position. These players are now looking to strengthen their position further through acquisition activities and encouraging regulatory support.

Key Industry Developments:

April 2016: Allergan plc received Positive Opinion by the Committee for Medicinal Products for Human Use for the commercial release of ENZEPI, the company’s flagship pancreatic enzyme replacement therapy (PERT) for patients with exocrine pancreatic insufficiency (EPI), in the European Union.
May 2018: VIVUS, Inc. announced its acquisition of product rights of Janssen Pharmaceuticals’ PANCREAZE, a pancreatic enzyme preparation consisting of pancrelipase, which is an extract derived from porcine pancreatic glands to treat EPI.
Key Industry Players:

AzurRx
AbbVie Inc.
CHIESI Farmaceutici S.p.A.
Allergan
Janssen Pharmaceuticals, Inc.
Table of Content from Exocrine Pancreatic Insufficiency Therapeutics Market:

Introduction
Research Scope
Market Segmentation
Research Methodology
Definitions and Assumptions
Executive Summary
Market Dynamics
Market Drivers
Market Restraints
Market Opportunities
Key Insights
Prevalence of Major Disorders Associated With Exocrine Pancreatic Insufficiency
Pipeline Analysis
Recent Industry Developments Such as Mergers, Partnerships & Acquisitions
Regulatory Scenario
New Product Launches
Global Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2015-2026
Key Findings / Summary
Market Analysis, Insights and Forecast – By Therapy
Pancreatic Enzyme Replacement Therapy (PERT)
Creon
Zenpep
Others
Nutritional Therapy
Market Analysis, Insights and Forecast – By Distribution Channel
Hospital Pharmacies
Retail Pharmacies & Drug Stores
Others
Market Analysis, Insights and Forecast – By Country
North America
Europe
Asia Pacific
Rest of the World
North America Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2015-2026
Key Findings / Summary
Market Analysis – By Therapy
Pancreatic Enzyme Replacement Therapy (PERT)
Creon
Zenpep
Others
Nutritional Therapy
Market Analysis – By Distribution Channel
Hospital Pharmacies
Retail Pharmacies & Drug Stores
Others
Market Analysis – By Country
S.
Canada
TOC Continued…..

About Us:
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights, we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com

Linkedin | Twitter | BLogs

This release was published on openPR.